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Neuroblastoma (NB) is a heterogeneous, and particularly malignant childhood neoplasm in its higher stages, with a propensity
to form metastasis in selected organs, in particular liver and bone marrow, and for which there is still no efficient treatment
available beyond surgery. Recent evidence indicates that the CXCR4/CXCL12 chemokine/receptor axis may be involved in
promoting NB invasion and metastasis. In this study, we explored the potential role of CXCR4 in the malignant behaviour of
NB, using a combination of in vitro functional analyses and in vivo growth and metastasis assessment in an orthotopic NB
mouse model. We show here that CXCR4 overexpression in non-metastatic CXCR4-negative NB cells IGR-NB8 and in moderately
metastatic, CXCR4 expressing NB cells IGR-N91, strongly increased tumour growth of primary tumours and liver metastases,
without altering the frequency or the pattern of metastasis. Moreover shRNA-mediated knock-down experiments confirmed
our observations by showing that silencing CXCR4 in NB cells impairs in vitro and almost abrogates in vivo growth. High levels
of CXCL12 were detected in the mouse adrenal gland (the primary tumour site), and in the liver suggesting a paracrine effect of
host-derived CXCL12 on NB growth. In conclusion, this study reveals a yet unreported NB-specific predominant growth and
survival-promoting role of CXCR4, which warrants a critical reconsideration of the role of CXCR4 in the malignant behaviour of
NB and other cancers.
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INTRODUCTION
Neuroblastoma (NB), the most common and deadly solid tumour
in childhood, originates from primitive cells of the sympathetic
nervous system. NB displays a very heterogeneous behaviour at
clinical, biological, and genetic levels. The majority of patients
presents at diagnosis with an aggressive and metastatic disease for
which little improvement in therapeutic options has been made in
the last decade [1]. Metastatic tumour cell dissemination of
advanced stage and highly malignant NB tumours mainly occurs
in the bone marrow, bone, liver, and skin. Organ-specific
metastasis, known to involve events in both the tumour cells and
the target tissue, represents an intriguing and yet unresolved
phenomenon [2,3]. Chemokines are small, cytokine-like proteins
forming a large superfamily, originally discovered as essential
mediators of leukocyte chemoattraction in inflammation and
immune cell homing and recirculation. Upon binding to their
cognate seven-transmembrane spanning G-protein-coupled recep-
tors, they induce integrin activation and cytoskeletal rearrange-
ment promoting cell adhesion and directional migration [4–6].
Emerging evidence indicates that the chemokines and their
receptors play an important role in tumour biology [7,8]. CXCR4
is the chemokine receptor most commonly found on tumour cells.
It has been reported expressed in at least 23 different types of
cancers [9]. In a number of cancer types, binding of its cognate
ligand CXCL12 [10] was reported to mediate directed migration
of cancer cells to sites of metastasis [9,11]. Recent reports indicate
that CXCR4 is commonly expressed on NB metastasis in the bone
marrow and that it may be actively contributing to NB tumour cell
homing to the bone marrow [12]. However, these observations are
still controversially discussed [13].
There is emerging evidence that the tumour environment plays
a critical role in modulating the behaviour of primary or
metastatic tumour cells. The appropriate microenvironment and
vascular niche involved in metastasis initiation can only be
provided by the orthotopic site [14]. Hence, the use of in vivo
orthotopic models, faithfully reproducing the tumour microenvi-
ronment, is essential for the analysis of metastasis-related
mechanisms [15–18].
In this study, we investigated the contribution of CXCR4 to NB
progression in vitro and in vivo and demonstrate that CXCR4
overexpression promotes NB primary and secondary tumour
growth but not NB invasion. Using an in vivo orthotopic model
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[19], we demonstrate that CXCR4 has no significant influence on
the number or pattern of NB metastasis. In contrast, the strong
growth-promoting effect observed may represent the main role of
CXCR4 in tumour progression. These results warrant a critical
reconsideration of the role of CXCR4 in NB tumour progression.
MATERIALS AND METHODS
Cell lines and culture
IGR-NB8 cell line was derived from a xenotransplanted human
stage 3 abdominal NB [18]. IGR-N91 cell line was derived from
a stage 4 NB infiltrated bone marrow [20]. The cell line SH-SY5Y
was used as a CXCR4 positive control [21]. The prostate cancer
cell line PC3, represents another positive control for its described
and generally accepted properties upon CXCR4 overexpression
[22]. Unless specified, cells were cultured in Dubelcco’s modified
Eagle’s medium (DMEM) supplemented with 2 mmol/l L-
glutamine, 10 mg/ml gentamycin, and 10% fetal calf serum
(FCS) (AMIMED). For growth and invasion assays, cells were
cultured in N2-supplemented DMEM, a serum-free medium
specifically defined to support the growth of neuronal cells [22,23]
CXCR4 overexpression
A pMIGR-EGFP vector encoding for the enhanced green
fluorescent protein (EGFP) with or without the chemokine
receptor CXCR4 gene was inserted by retroviral mediated
infection into IGR-NB8, IGR-N91 and PC3 cells as previously
described [19]. The CXCR4 containing plasmid was sequenced to
verify its integrity [12].
GFP-overexpressing cells were sorted by fluorescence activated
cell sorting (FACS) and cloned. Control GFP and selected CXCR4
clones were analysed by FACScan (Becton Dickinson), using the PE–
labelled 12G5 monoclonal antibody from BD Pharmingen to
measure and quantify CXCR4 surface expression levels.
In vivo growth
Animal engraftments, tumour and metastases growth records were
performed as previously described [19]. Athymic locally bred Swiss
nude mice were engrafted with 66105 of NB8-E6 (8 animals), NB8-
CXCR4-C3 (8 animals), N91-E2 (8 animals), and N91-CXCR4-14
(13 animals) cells in 15 ml DMEM in the left adrenal gland. For
knock-down experiments, 26106 N91-pAB303, N91-shCXCR4-
CS1 and N91-shCXCR4-CS2 cells in 50 ml DMEM were injected.
Ten animals were used for each group. One mouse in the N91-
pAB303, 4 in the N91-shCXCR4-CS1 and 2 in the N91-shCXCR4-
CS2 group died of perioperative complications.
Micrometastases were detected by PCR and macroscopic
metastases by morphological examination and/or GFP-IHC as
previously described [19].
Cell proliferation assay
Cell proliferation was assessed using the MTS/PMS cell pro-
liferation kit from Promega as described earlier [24]. Twenty
thousand cells per well were seeded in either 10% FCS or 2%
FCS. Where indicated, growth assays were performed in the
presence of CXCL12 (100 ng/ml).
ERK1/2 phosphorylation
As described [25], cells were serum-starved overnight and washed
once with PBS prior to experimentation. Aliquots of 106 cells were
stimulated with CXCL12 (Preprotech) for indicated time.
Incubations were stopped by the addition of 500 ml SDS-PAGE
buffer. To detect phospho-ERK1/2, membranes were first probed
with a phospho-specific antibody (Cell Signalling) and then stripped
and re-probed with the antibody against the total ERK1/2.
CXCL12 ELISA
An ELISA assay (R&D Systems) was used to quantify the
production of CXCL12 by NB cell lines, normal mice tissues,
and orthotopically grown primary tumours. Tissue extracts were
prepared as described [26] and were processed following R&D
Systems’s instructions.
Chemotaxis and invasion assays
Cell migration was measured using Transwell CostarH cell culture
chambers with polycarbonate filters of 8 mM porosity. Briefly,
2.56105 cells suspended in serum-free medium (SFM) were seeded
in the upper compartment of a two chambers system, as described
[27]. The lower compartment was filled with SFM with or without
100 ng/ml CXCL12. Migration assays were performed in the
presence or absence of a specific CXCR4 receptor inhibitor, 4F-
benzoyl-TN14003 [28]. The cells were allowed to settle down for
4 hours. After washing, membranes were fixed with 4% para-
formaldehyde in PBS for 10 min and stained with haematoxylin.
Non migrated cells were scraped from the upper side of the filter,
and migrated cells on the lower side counted by light microscopy.
For invasion assays, the 8 mm polycarbonate membranes of the
Transwell inserts were coated with 50 ml of 0.8 mg/ml of MatrigelH.
The lower chamber was either supplemented with DMEM-N2
medium alone or with DMEM-N2-containing 100 ng/ml CXCL12.
Fifty thousand overnight serum-starved cells were plated in the
upper chamber. After 48 h incubation at 37uC, membranes were
processed and number of invading cells counted as above.
Knock-down of CXCR4 by shRNA
Stable downregulation of CXCR4 was achieved by RNA
interference using short hairpin RNAs [29]. A published sequence
from shRNA which specifically and efficiently down regulates
CXCR4 was used as previously reported [30,31]. The sequences
were checked by sequencing a PCR-amplified region containing
the oligonucleotide. The H1 promoter and the shRNA cassette
were sub-cloned into the BamHI/SalI sites of the lentiviral vector
pAB286 containing the SV40 promoter-puromycin acetyltransfer-
ase cassette [32]. The pAB303 lentiviral vector which contains the
H1 promoter alone, without shRNA sequence, was used as
a negative control (gift from R. Iggo, Aberdeen, Scotland) [32].
Lentiviruses were produced by co-transducing the lentiviral vector
plasmid containing the shRNA (10 mg) and the second generation
packaging plasmids (3.5 mg pMD2-VSVG, 6.5 mg pCMVDR8.91)
into 293T (ATCC CRL-11268) all vectors but pAB303 kindly
provided from D. Trono, EPFL, Lausanne, Switzerland. Infection
of target cells were done by over-night incubation at 37uC in virus-
containing media in presence of 8 mg/ml polybrene (hexadime-
thrindibromide, Fluka). Twenty-four hours post-transfection, the
lentivirus containing supernatant was used to infect the IGR-N91
cell line. Selection was started 48 h after infection with 5 mg/ml
puromycin (Sigma-Aldrich, Steinheim, Germany). Puromycin
resistant infected cells were selected 24 h post-infection.
CXCR4 protein expression knock-down in shRNA-transduced
cells was determined by FACS analyses.
Statistical analyses
Statistcial analyses were performed using GraphPadPrism 4.0.
Two-way ANOVA with Bonferroni post-test corrections was
performed to compare cell growth in 10% and 2% FCS. Student’s
t test was performed for cell growth in the presence or absence of
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CXCL12. Fisher’s exact test was performed to compare the
number of metastasis-bearing animals. Mann-Whitney test was
used to compare in vivo tumour growth. A p,0.05 was considered
to represent signficance and p,0.01 was considered to be highly
significant.
RESULTS
Expression of the chemokine receptor CXCR4 on NB
cell lines
Constitutive cell surface CXCR4 expression, measured by flow
cytometry (FC) in a panel of NB cell lines was variable among the cell
lines tested (not shown). As shown in Figure 1, two selected invasive
NB cell lines, IGR-N91, SH-SY5Y, displayed constitutive levels of
CXCR4 surface protein expression (54% and 97% positive cells
respectively), while the non-invasive IGR-NB8 cell line expressed
very little if any surface CXCR4 (1.48% positive cells).
To explore the putative role of CXCR4 in NB malignant
behaviour, we stably overexpressed CXCR4 by retroviral trans-
duction in two NB cell lines with well-characterized growth
properties: IGR-NB8, a non metastatic line, and IGR-N91, which
forms metastases when implanted orthotopically [19]. CXCR4-
transduced clones, randomly selected from IGR-NB8 (NB8-
CXCR4-B2, C3, and -E9) or IGR-N91 (N91-CXCR4-11, -14, -
19), displayed high and similar levels of surface CXCR4
expression. Mock transduced NB8-E6 cells remained CXCR4
negative, while and N91-E2 cells express slightly lower levels of
CXCR4 compared to parent cells. (Figure 1).
CXCR4 increases IGR-NB8 in vivo growth.
To evaluate the role of CXCR4 in the development of site-specific
metastasis we used the orthotopic NB mouse model that strongly
implies the role of the tumour microenvironment on tumour
progression. Parental lines and CXCR4 transduced clones were
analysed in vivo for primary (orthoptopic) tumour growth,
metastatic dissemination, and organ specific secondary growth.
In vivo experiments were first performed with the NB8-E6 cells,
previously shown to be able to induce tumours in the orthotopic
model, but unable to develop metastases. Two randomly selected
control NB8-E6 and CXCR4-overexpressing NB8-CXCR4-C3
cell lines were implanted in the left adrenal gland of nude mice.
The mice were examined by echography at day 33, 53, 69, and
102 for the presence of tumours. Six out of 8 animals (75%) in the
NB8-E6 group, and 7/8 mice (88%) in the group engrafted with
NB8-CXCR4-C3 developed a tumour, thus showing a similar
tumour take in mice engrafted with CXCR4-negative or CXCR4
positive NB8 cell line (Figure 2a).
As shown in Figure 2a, CXCR4 expression in the NB8 cell line
dramatically accelerated tumour growth. The first echographic
record performed at day 33 after implantation, already revealed
the presence of tumours with a volume between 100 and 200 mm3
in two mice in the NB8-CXCR4-C3 group, whereas no tumours
were detected in the control group. At day 53, 7/8 mice in the
NB8-CXCR4-C3-implanted group of mice had developed
tumours with a mean volume of 1727 mm3, which required the
immediate sacrifice of all animals in this group, while in the
control group tumours were barely detectable at that time point.
Figure 1. CXCR4 cell surface expression. IGR-NB8 and IGR-N91, two well characterized NB cell lines, and transduced cell lines/clones were analyzed
for their cell surface CXCR4 expression by flow cytometry (FACS). Percent positive cells is indicated as well as the mean fluorescent intensity (brackets)
of the CXCR4 staining. The NB cell line SH-SY5Y constitutively expressed high levels of CXCR4 as previously described [21]. The prostate cancer cell
line PC3 showed comparable levels of CXCR4 expression upon transduction as NB8-CXCR4 and N91-CXCR4 clones.
doi:10.1371/journal.pone.0001016.g001
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At sacrifice (day 102), the mean volume of NB8-E6 tumours was
only 48 mm3. These results reveal that the time interval between
engraftment and detectable tumour growth was considerably
reduced in mice engrafted with NB8-CXCR4-C3 cells compared
to NB8-E6, thus demonstrating that CXCR4 expression in the
CXCR4-negative cell line NB8 dramatically accelerated ortho-
topic tumour growth in vivo (Figure 2a).
CXCR4 does not induce metastatic dissemination of
IGR-NB8 cells
One of the major proposed contribution of CXCR4 to NB
progression was the promotion of site-specific metastasis [21]. We
therefore investigated whether CXCR4 overexpression in NB
tumour cells could influence organ-specific invasive behaviour in
our in vivo model. Major target and control organs of tumour-
bearing mice were macroscopically analysed for the presence of
metastases. No macroscopic metastasis was detected in either
group. Micrometastases as detected by GFP-PCR-based analysis,
revealed GFP-signals in the lungs of a minority of NB8-E6 and
NB8-CXCR4-C3-engrafted animals, and in the livers of 2/6 NB8-
E6 and 4/7 NB8-CXCR4-C3 bearing animals, respectively. No
signal was found in blood, muscle, and bone marrow of both
groups of mice (Figure 2b). All mice livers were further investigated
by GFP-immuno-histochemistry where no microscopic metastasis
was detected (data not shown).
These results indicated that enhanced CXCR4 expression in the
IGR-NB8 cells tremendously accelerated the growth of the primary
tumour. In contrast, CXCR4 overexpression was not sufficient to
induce metastatic dissemination in this orthotopic model.
CXCR4 increases IGR-N91 in vivo growth
Since the IGR-NB8 cell line is a non-metastatic cell-line we were
concerned that it may lack essential invasive elements, thereby
masking a potential metastasis-promoting effect of CXCR4. We
therefore repeated the experiment with IGR-N91, a cell line which
is capable of forming metastases when injected orthotopically, but
not when injected s.c. [19]. Specifically, we injected the CXCR4
overexpressing cell line N91-CXCR4-14 and N91-E2, the mock-
transduced control. Out of 13 mice implanted with N91-CXCR4-
14 cells, 12 developed a tumour, with a mean volume of
1390 mm3 at 49 days, whereas in the control group, 8/8
developed a tumour, reaching a mean volume of 15 mm3 after
49 days (Figure 2c). As observed with the IGR-NB8 derived cells,
the tumour take was similar in both groups. N91-CXCR4 tumours
also grew considerably faster, reaching nearly 100 fold larger
volumes than N91-E2 tumours.
Figure 2. In vivo orthotopic tumour growth and metastasis. Tumour growth measured in mice engrafted with NB8-E6 and NB8-CXCR4-C3 (a), and
N91-E2 and N91-CXCR4-14 (c) The mean tumour volume 6 S.D. as measured by echo-doppler at indicated days after implantation is shown. The
tumour take expressed as number of mice with tumour/total mice and percent mice with tumours is indicated. (b) and (d) Detection of metastases in
mice engrafted with either NB8-E6/NB8-CXCR4-C3 or N91-E2/N91-CXCR4-14 cells. Macroscopic liver metastases were detected by gross examination.
Micrometastases were detected in lung, bone marrow, muscle and blood by GFP-PCR. Bars represent percentages of mice with macroscopic liver
metastases or GFP-PCR positive signals in indicated organs per tumour bearing animal.
doi:10.1371/journal.pone.0001016.g002
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CXCR4 does not enhance metastatic dissemination
of IGR-N91 cells
The examination of the metastatic pattern of these tumours
revealed that 6/12 mice in the N91-CXCR4-14 group had at least
one macroscopic liver metastasis, whereas in the control group 2/8
mice developed macroscopic hepatic metastases (Figure 2d). The
volume of liver metastases in N91-CXCR4-engrafted group of
mice was much larger (250 to 1000 mm3) when compared to the
N91-E2 group (less that 100 mm3). GFP-PCR analyses revealed
the presence of micrometastases in 58% of the lungs and 50% in
the bone marrow of mice with N91-CXCR4-14 tumours, versus
50% and 25% in the N91-E2 group. These differences observed in
the occurrence of micro- and macro-metastases were nevertheless
not statistically significant (Fisher’s exact test: p = 0.38), while the
differences in the volume of macroscopic liver metastases in the
two groups were highly significant. No GFP-PCR signal was
detected in the blood or in the control organ (muscle) in either
group.
These results reveal that CXCR4 overexpression in the
metastasis-competent IGR-91 NB cells has a strong and pre-
dominant effect on primary and secondary tumour growth
(increase of the metastases volume). Even in such orthotopic
model, a statistically significant increase of metastases frequency
could not be demonstrated.
Functional CXCR4 supports in vitro NB cell growth
and survival
To gain further insight into the distinct molecular mechanisms
responsible for the CXCR4/CXCL12 axis mediated effects on NB
progression rather than site-specific invasion, we next explored the
effects of CXCR4 over-expression on in vitro proliferation, survival,
migration, and invasion of these NB cells.
The growth and survival of different CXCR4-expressing cell lines
was measured in vitro in complete medium (10% FCS) or in stress
conditions (2% FCS) (Figure 3a). Growth curves were established
over a 96 hours period. In the presence of 10% FCS, the results
revealed a non significant difference in the growth capacity of 2
NB8-CXCR4-expressing clones as compared to NB8-E6. A
significantly enhanced growth of one clone (NB8-CXCR4-E9) as
compared to the control cells was observed. (Figure 3a). Thus in vitro,
the IGR-NB8-E6 and NB8-CXCR4-C3 cells selected for in vivo
studies, did not show different growth properties. In contrast,
addition of the CXCL12 ligand significantly increased the growth of
CXCR4-overexpressing NB8-CXCR4-C3 cells, but not that of the
control NB8-E6 cells (Figure 3b).
The CXCR4-expressing clones and their controls were exposed
to suboptimal culture conditions (2% FCS). These stress conditions
significantly impaired NB8-E6 growth, while they only slightly
affected the growth of the three CXCR4 expressing clones,
Figure 3. Effect of functional CXCR4 overexpression in NB cell lines. (a) In vitro growth of NB8-E6, NB8-CXCR4-C3, -B2, and -E9 cells, in 10% (black
squares) or 2% serum (open squares). (statistical analysis by two-way ANOVA and Bonferroni correction) A representative of three independent
experiments is shown. (b) In vitro growth of NB8-E6 and NB8-CXCR4-C3 cells in the presence of 100 ng/ml CXCL12 (black squares) or in medium alone
(open squares). (c) Western blot analysis of ERK1/2 phosphorylation in response to CXCL12 in CXCR4-transduced cells.
doi:10.1371/journal.pone.0001016.g003
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indicating a significant (p,0.05) CXCR4-mediated enhanced
survival in stress conditions (Figure 3b).
CXCR4 overexpression in the IGR-N91 cells did not further
increase their in vitro growth or survival (not shown).
Extracellular regulated kinases (ERK) 1/2 are activated by
phosphorylation in response to various extracellular signals,
including the binding of CXCR4 to its unique ligand, CXCL12,
[22]. To test the functionality of endogenous and transduced
CXCR4 in NB cells, we monitored CXCL12-mediated ERK
1/2 phosphorylation. As shown in Figure 3c, no significant
increase in ERK1/2 phosphorylation was detected in the
control NB8-E6 cells in response to CXCL12 up to 30 minutes.
In contrast, in N91-E2, expressing endogeneous CXCR4 and in
NB8-CXCR4-C3, and N91-CXCR4-14 cells with exogeneous
CXCR4 overexpression, CXCL12 stimulation increased ERK1/
2 phosphorylation already after 1 minute. Total ERK1/2
protein was unchanged at all time points (Figure 3c). Altogether
these assays confirmed that the CXCR4 receptor, either
endogenous or exogenous, is functional and able to transduce
CXCL12-mediated intracellular signals in NB cells, implicating
the ERK pathway as potential mediator of CXCR4-induced
proliferation.
CXCR4 induces cell migration in response to CXCL12
We next tested whether CXCR4 increased directed migration. To
this purpose, CXCL12-mediated cell migration was measured in
NB cells. As shown in Figure 4a, none of the cell lines were able to
migrate in the absence of the ligand. In the presence of 100 ng/ml
of CXCL12, migration was induced in IGR-N91 cells and in all
three NB8-CXCR4 clones but not in the CXCR4-negative NB8-
E6 cells. Migration of N91-CXCR4-14 clone was not enhanced as
compared to that of N91-E2 control cells in response to CXCL12.
Migration assays were then performed in the presence of
CXCL12 6 the CXCR4 TN14003 inhibitor. TN14003 did not
alter the migration of the control NB8-E6 cell line, but it
attenuated chemotaxis of CXCR4-expressing clones in a dose-
dependent manner (Figure 4a), indicating a specific CXCR4-
promoting chemotaxis in IGR-NB8 and IGR-N91 cells.
CXCR4 does not mediate in vitro invasion of NB cells
in response to CXCL12
In order to form metastases in vivo, malignant cells need not only to
migrate, but also to invade basal membranes and the surrounding
tissue. To investigate the role of CXCR4/CXCL12 axis in
Figure 4. NB8 cell migration and invasion in vitro. (a) Migration of NB8-E6, N91-E2, and CXCR4-overexpressing clones (NB8-CXCR4-C3, -B2, -E9, N91-
CXCR4-14) towards CXCL12, in absence or presence of the CXCR4 blocker (TN14003 inhibitor). Results of a representative experiment are shown and
are expressed as mean number of cells in one field. Five fields were counted for each result. The experiment was performed in triplicates and
repeated three times. Error bars indicate S.D. (b) Invasion of SH-SY5Y, NB8 and N91 control and CXCR4 transduced clones through MatrigelH-coated
membranes in N2 supplemented serum-free medium alone, with or without CXCL12. CXCL12-mediated invading cells (invaded cell in the absence of
CXCL12 have been subtracted) -in a typical field are shown. The mean number of invading cells in 5 fields is given. Error bars indicate S.D. (* indicates
p,0.05, Student’s t-test)
doi:10.1371/journal.pone.0001016.g004
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promoting cell invasion we performed an in vitro MatrigelH
invasion assay. The different cell lines were placed in the upper
chamber of a TranswellH filter coated with MatrigelH, and cells
were allowed to invade for 48 hours in response to CXCL12
present in the lower compartment [33].
As shown in Figure 4b, none of the cell lines were invasive in
serum free, N2-supplemented medium, whereas control cells
SH-SY5Y were invasive in these conditions. In the presence of
CXCL12, the N91-E2 cells were only slightly invasive, whereas
the NB8-E6 cells were not (Figure 4b). As a control, the prostate
cancer cell line PC3, reported to be more invasive when over-
expressing CXCR4 [22] was transduced with the same CXCR4
containing plasmid. The CXCR4 transduced cells PC3-CXCR4
cells were significantly more invasive in vitro than control cells
(Figure 4b) (Student’s t-test: p,0.05). However, despite high and
similar CXCR4 induced surface expression in NB8-CXCR4,
N91-CXCR4 and PC3 cells (Figure 1), the invasive capacity of
NB8-CXCR4 and N91-CXCR4 cells was not significantly
enhanced as compared to control mock-transduced cells, while
significant enhanced invasion of CXCR4-PC3 cells was observed.
This suggests a tumour type specific effect of CXCR4 in
promoting invasion.
As NB8-CXCR4 overexpressing cells displayed enhanced in vitro
migration but not invasion nor in vivo metastatic dissemination, we
investigated whether the lack of invasive properties was due to
a lack of proteolytic activities in the NB8 or N91 cells by
measuring MMP-2 and -9 activities in SH-SY5Y cells culture
supernatant, N91-E2, NB8-E6 and NB8-CXCR4 clones using
a zymography assay (Figure S1). Data obtained ruled out an
implication of MMP-2 and MMP-9 in the lack of metastatic
properties of NB8 cell line used (Figure S1).
The CXCR4 ligand, CXCL12 is produced by the
tumour microenvironment
The above data indicate that CXCR4 enhances tumour growth in
vivo and NB cell proliferation in vitro in response to CXCL12. To
collect evidence whether CXCL12 may be a factor relevant to
tumour growth in vivo, we measured the concentration of
CXCL12 in the primary and secondary tumours as well as in
selected host tissues (Figure 5). Presence of CXCL12 could be
measured by ELISA in several nude mouse organs, and the highest
levels of CXCL12 were found in the adrenal gland, the natural
primary tumour microenvironment for neuroblastoma. High
CXCL12 levels where also found in the liver, lung and muscle,
while almost undetectable CXCL12 were measured in bone
marrow (not shown) (Figure 5). Surprisingly, no direct relationship
was observed between expression levels of CXCL12 in the
different organs and the pattern of NB metastasis. In contrast, the
high levels of CXCL12 detected in the adrenal glands and liver,
may be related to the increased primary NB tumour and
secondary metastatic growth in these tissues.
Knockdown of CXCR4 by shRNA
In order to confirm the specific role of CXCR4 in NB, we
analysed the growth properties of CXCR4 knock-down cells.
Since we observed that in vitro growth, migration and invasion
were not further enhanced by exogeneous CXCR4 overexpression
in IGR-N91 cells with conctitutive endogeneous CXCR4 expres-
sion, we knocked-down endogeneous CXCR4 in IGR-N91 cells.
Stable knock-down of CXCR4 was achieved by transduction of
IGR-N91 cells with shRNA lentiviral constructs. Clones were
screened for efficient silencing of CXCR4 by real-time PCR.
CXCR4 mRNA levels of cells transduced with the empty vector
pAB303 were used as reference. Resulting cell surface CXCR4
expression, as illustrated in Figure 6a, shows that strong and
efficient knock-down of CXCR4 was achieved in both N91-
shRNA-CS1 and N91-shRNA-CS2 clones as compared to N91-
pAB303 control cells (5.3% and 7.7% vs 53% CXCR4 positive
cells respectively).
Knockdown of CXCR4 impairs in vitro growth
CXCR4 overexpression in NB cells increased in vitro cell growth
under serum deprived conditions and in vivo tumour growth. Cells
where CXCR4 has been knocked down by shRNA were tested for
their in vitro growth capacities. As shown in figure 6b, Both N91-
shCXCR4-CS clones revealed impaired in vitro growth, not only in
serum deprived culture conditions (2% FCS) but also in normal
conditions (10% FCS). Interestingly the difference was only
apparent at time point 96 h (Fig 6b).
Knockdown of CXCR4 abrogates in vivo growth
We then specifically investigated the in vivo growth capacities of
control N91-pAB303, N91-shCXCR4-CS1 and N91-shCXCR4-
CS2 cells. For this purpose cells were orthotopically injected in
nude mice and tumour growth measured every other week. In this
experiment, all mice were sacrificed at day 44 when large tumours
were present in the control group (N91-pAB303). As shown in
figure 6c, at day 44, N91-pAB303 tumours were significantly
larger (mean volume 703 mm3) than CXCR4 knocked-down N91-
shCXCR4-CS1 and N91-shCXCR4-CS2 tumours (mean volume
74.8 mm3 and 9.7 mm3 respectively) (p,0.05 Mann Whitney
test).
DISCUSSION
Recent reports suggest a role for CXCR4 and its ligand CXCL12
in the malignant behaviour of cancer cells. In particular, the
CXCR4/CXCL12 axis has been involved in metastasis formation,
increased survival of cancer cells under harsh conditions, and
establishment of a tumour promoting cytokine/chemokine
network [7–9,34–38]. The specific involvement of the CXCR4/
CXCL12 axis in cell proliferation, and organ-specific metastasis
has been partially addressed and remains controversial in some
Figure 5. CXCL12 production in mouse tissues and NB tumours. The
production of CXCL12 was measured by ELISA in normal mouse tissues,
as well as in the different clones, and primary tumours. Results of
triplicates are expressed as pg of CXCL12 per mg of extracted protein.
One representative of three independent experiment is shown.
Experiments were performed in triplicates.
doi:10.1371/journal.pone.0001016.g005
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tumour systems, including NB [13]. It has been proposed that
CXCR4 expression may be a mechanism by which NB cells
metastasise at specific sites [12,21]. A recent study on NB cell lines
and patients samples, however, raised doubts on the implication of
CXCR4 in the metastatic dissemination. Even though CXCR4
was expressed on bone marrow metastases, it appeared not to be
functional [13].
The present study was initiated to address this controversial
topic and to investigate the consequences of CXCR4 expression
on growth and metastatic behaviour of two NB cell lines in vivo.
The question whether CXCR4 is sufficient to initiate and to
increase NB metastases upon orthotopic implantation has not been
addressed yet. We used a murine orthotopic model of NB which
implies the influence of the natural tumour microenvironment on
tumour progression and mimics human NB behaviour [19]. The
CXCR4/CXCL12 axis-mediated mechanisms were then further
investigated in vitro.
Our in vivo data indicate that almost all mice orthotopically
engrafted with NB cells developed a tumour (Figure 2a and 2c).
Surprisingly, overexpression of CXCR4 did not lead to induction
of metastases in the non-metastatic NB cell line IGR-NB8 and did
not increase the frequency of metastases formed by the metastatic
IGR-N91 cell line, which constitutively expresses moderate levels
of CXCR4 [19] (Figure 2d, Fisher’s exact test: p = 0.38). CXCR4-
overexpression in both cell lines, however, promoted a CXCL12-
dependent chemotaxis, thereby demonstrating that in both cells
lines ligand-bound CXCR4 can elicit a motility phenotype. This
observation is consistent with previous reports linking CXCR4
expression with tumour cell motility and chemotaxis in response to
CXCL12 [5–7,39–41]. The controversial data on the influence of
CXCR4 on metastasis frequency may be explained by the
different in vivo assays used, as well as the different tumour types
analysed. [7,22,34–36,38]. While neither NB8-CXCR4 nor N91-
CXCR4 clones showed any increased capacity to invade
MatrigelH in response to CXCL12, CXCR4 overexpressing PC3
prostate cancer cells indeed showed increased in vitro invasive
capacity [30]. This observation made in another cancer type
confirms previous reports [22] and suggests that the pro-invasive
effects of CXCR4 may be tumour type specific.
On the other hand, increased metastatic capacity of CXCR4
expressing NB cells and increased CXCR4 expression in metastatic
NB tumour cells as observed by Zhang et al. [12], may be explained
by the i.v, implantation of tumour cells, thus focussing on late and
bypassing the initial steps of metastasis. However, in an orthotopic
model of neuroblastoma, which includes all steps of the metastatic
process, CXCR4 is not sufficient to induce or increase metastasis,
but fully manifest its growth promoting effects.
The reason for the lack of increased invasion and metastasis upon
CXCR4 overexpression in NB cells remained elusive. While for
IGR-NB8 cells it could be argued that they lack essential invasive or
metastatic properties, this cannot be true for IGR-N91 cell lines
overexpressing CXCR4, since the parental line has already
metastatic capacities. Also, MMP-2 and -9 appear not to be factors
limiting invasion and metastatis in these cells. This finding indicate
that neither CXCR4 expression nor MMP-2 and –9 are sufficient to
confer invasive and metastatic properties to NB cells.
Figure 6. (a) FACS profiles of shRNA-mediated cell surface CXCR4 silencing in N91-shRNA-CS1 and N91-shRNA-CS2 clones and N91-pAB303 control
cells. Percent positive cells is indicated as well as the mean fluorescent intensity (brackets) of the CXCR4 staining. (b) In vitro growth capacities of N91-
shRNA-CS1, N91-shRNA-CS2 clones and N91-pAB303 control cells. (c) In vivo growth capacities of IGR-N91 cells were CXCR4 has been knocked down
by shRNA. Comparison of tumour volumes after 44 days when mice were sacrificed. * indicates p,0.05 (Mann-Whitney test).
doi:10.1371/journal.pone.0001016.g006
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It could also be argued that the time before sacrifice of animals
bearing NB8-CXCR4-C3 tumours after only 53 days, was too
short and not sufficient to allow metastases to develop. This
appeared unlikely, since macroscopic liver metastases were
observed in the N91-E2 group already after 49 days. Furthermore,
based on our experience in this model, bone marrow metastases
usually occur within 50 days after tumour engraftment [19].
We could also rule out that NB8 clones expressed too low levels
of CXCR4 to induce invasion or metastasis, as the levels of
expression were comparable to that of the PC3-CXCR4 cells,
which show enhanced invasive properties.
In contrast, CXCR4 overexpression induced a remarkable
enhancement of, in vivo tumour growth, representing the essential
observation of this study. Both CXCR4 overexpressing cell lines
NB8-CXCR4-C3 and N91-CXCR4-14 displayed a considerably
faster growth compared to their respective controls. Even N91-
CXCR4-14 cells which did not show enhanced in vitro growth,
proliferate significantly faster in vivo, indicating that endogeneous
CXCR4-mediated effects on growth can be further increased and
are most likely dependent on the tumor environment. Interestingly,
secondary growth was also enhanced: macroscopic liver metastases
in the N91-CXCR4-14 were all larger than 500 mm3 whereas the
N91-E2 metastases were smaller than 500 mm3. Such observation
strengthens the hypothesis that CXCR4/CXCL12 axis participates
in the promotion of in vivo NB cell proliferation, together with other
micro environmental factors, which need to be identified.
The impressive influence of CXCR4 on in vivo NB growth was
further supported by CXCR4 knock-down experiments. In vivo,
tumour growth of N91-shRNA-CS1 and N91-shRNA-CS2 clones
with reduced endogenous CXCR4 was almost totally abrogated
compared to N91-pAB303 control cells. This result confirms a role
not only for exogenous but also for endogeneous CXCR4 in NB
cell growth.
Under normal culture conditions i.e. in the presence of 10%
FCS the in vitro proliferation assays showed a moderately increased
growth of 2/3 NB8-CXCR4 clones compared to mock transduced
cells. This discrete growth promoting effect may be ligand
independent, considering that serum contains low levels of
CXCL12, or be a result of an autocrine signal from low amounts
of CXC12 produced by NB cells, as reported [22]. However, the
NB8-C3 clone, displaying a moderate in vitro and a strongly
enhanced in vivo growth, showed an increased in vitro growth in
response to CXC12, indicating that CXCL12/CXCR4 axis can
promote NB cell growth in vitro.
Moreover, NB8-CXCR4 cells were less sensitive to reduced
serum concentration (2% FCS). This finding indicates that
CXCR4 can, at least in part, compensate for serum depletion,
and increases survival in stress conditions, a hallmark of
malignancy. In NB8-CXCR4 cells CXCL12/CXCR4 activates
ERK1/2, with oncogenic and tumour-promoting activities,
consistent with the report by Hatse et al showing that endogenous
CXCL12/CXCR4 signalling axis is critical for neuroblastoma cell
survival and proliferation [42]. The pro-survival effect of CXCR4
observed in stress conditions may be due to the low amounts of
CXCL12 produced by NB cells. The in vitro effect of CXCR4 on
proliferation under reduced serum concentration was not observed
for the IGR-N91 cell line, which may be due to the fact that the
constitutive expression of CXCR4 in this cell line is already be
sufficient to confer in vitro survival advantages. Indeed, both N91-
shRNA-CS1 and N91-shRNA-CS2 CXCR4 silenced clones
showed reduced cell proliferation in vitro in 10% serum and in
reduced serum concentration.
Globally, our results show that exogeneous CXCR4 over-
expression in IGR-N91 does not further increase their in vitro
growth, migration and invasive properties, indicating that a subtle
threshold of endogenous CXCR4 level necessary and sufficient for
mediating growth, survival and migration is reached in these cells.
In contrast, their in vivo growth could be further enhanced,
probably by synergic signals provided by the tumour microenvi-
ronment.
The difference observed between the CXCR4 growth-pro-
moting effects in vitro and in vivo indeed suggests that CXCR4
participates to a more complex growth-promoting phenomenon
involving the tumour microenvironment. The high levels of
CXCL12 found in the primary tumour site (adrenal gland) and in
a major site of metastasis in our model (the liver) support the
notion that it may confer survival and proliferative advantages to
the NB cells and is consistent with a critical role of tumour
microenvironment in primary and secondary tumour growth. In
addition to a possible paracrine effect on tumour growth, the high
levels of CXCL12 measured in the primary site (adrenal gland),
represents a unique situation to NB where CXCL12 in the adrenal
gland could also serve to retain the malignant cells in the primary
site, rather than encourage them to metastasise [9]. Nevertheless,
some tumour cells, possibly equipped with unidentified particu-
larly invasive characteristics, do escape the primary tumour and
may then use the CXCR4/CXCL12 axis to specifically migrate
toward CXCL12 producing organs such as the liver. Thus the
large size of liver metastases observed in mice engrafted with N91-
CXCR4-14 cells, also supports a CXCR4-mediated enhanced
growth at secondary sites as at primary organs.
In conclusion, this in vivo and in vitro study reveals unique
growth-promoting effect of the CXCR4/CXCL12 axis in NB,
demonstrated by concordant CXCR4 gain and loss of function
assays. This study also emphasizes the importance to study tumour
growth and progression in orthotopic conditions. The role of the
microenvironment in the CXCR4-mediated growth and the
underlying explanation for the lack of increased metastatic spread
can only be identified using an orthotopic model [19]. In
particular, the differential expression levels of CXCL12 ligand in
primary and secondary target sites clarifies the role of the
CXCR4/CXCL12 system in NB progression: it strongly enhances
cell growth without increasing in vivo invasion.
Further in vitro molecular investigations will be needed to
identify the growth and survival pathways involved in such
CXCR4/CXCL12 responses. In particular, while some CXCR4-
overexpressing related proteins have been already reported,
a global CXCR4-mediated expression profile will be identified
[43]. Key molecules of the CXCR4 signalling pathway could be
new targets for specific NB therapeutic tools.
SUPPORTING INFORMATION
Figure S1 Zymographic assay of MMP-2 activity in NB cells
culture media. Equal cell number (0.86105) of different cell lines
was plated in SFM. After 12 hours starvation, medium was
collected and matrix metalloproteinase MMP-2, and MMP-9
activities were evaluated by gelatine zymography as described
[44]. Gels were stained with Coomassie blue to check for equal
sample loading. MMP-2 activity is represented as a band of
gelatinolysis at 72 KDa. MMP-9 activity was not detected (not
shown).
Found at: doi:10.1371/journal.pone.0001016.s001 (0.14 MB TIF)
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